Investigational Drug Information for Alisertib
✉ Email this page to a colleague
What is the development status for investigational drug Alisertib?
Alisertib is an investigational drug.
There have been 58 clinical trials for Alisertib.
The most recent clinical trial was a Phase 3 trial, which was initiated on September 1st 2018.
The most common disease conditions in clinical trials are Lymphoma, Neoplasms, and Lymphoma, B-Cell. The leading clinical trial sponsors are Millennium Pharmaceuticals, Inc., National Cancer Institute (NCI), and M.D. Anderson Cancer Center.
Summary for Alisertib
| US Patents | 0 |
| International Patents | 0 |
| US Patent Applications | 403 |
| WIPO Patent Applications | 365 |
| Japanese Patent Applications | 51 |
| Clinical Trial Progress | Phase 3 (2018-09-01) |
| Vendors | 93 |
Recent Clinical Trials for Alisertib
| Title | Sponsor | Phase |
|---|---|---|
| Phase II Study of Chiauranib Capsule in Advanced or Unresectable Soft Tissue Sarcoma | Shenzhen Chipscreen Biosciences Co.Ltd | Phase 2 |
| Phase II Study of Chiauranib Capsule in Advanced or Unresectable Soft Tissue Sarcoma | Sun Yat-sen University | Phase 2 |
| Alisertib and Pembrolizumab for the Treatment of Patients With Rb-deficient Head and Neck Squamous Cell Cancer | National Cancer Institute (NCI) | Phase 1/Phase 2 |
Clinical Trial Summary for Alisertib
Top disease conditions for Alisertib
Top clinical trial sponsors for Alisertib
US Patents for Alisertib
| Drugname | Patent Number | Patent Title | Patent Assignee | Estimated Expiration |
|---|---|---|---|---|
| >Drugname | >Patent Number | >Patent Title | >Patent Assignee | >Estimated Expiration |
